While thousands of people continue to line up for mesotherapy and Lipodissolve injections to get rid of stubborn body fat, others are steering clear of these potentially dangerous fat reduction treatments in hopes of a safer, more effective procedure.
Researchers at Kythera Biopharmaceuticals, Inc. are testing the latest liposculpting agent called ATX-101. This injection is designed to break down submental fat, and according to Keith Leonard, the President and CEO of Kythera, may soon become the best product for localized fat reduction.
Mesotherapy is a European non-surgical body sculpting technique that involves injecting a special concentration of vitamins, minerals and enzymes into the body to break down fatty tissue; Lipodissolve works in a similar fashion, but the 'cocktail' is a combination of phosphatidylcholine/deoxycholate (PCDC), plant extracts and alpha lipid acid. However, hundreds of patients have reported side effects including tissue swelling, bruising and even deemed these procedures to be ineffective.
Will Kythera's product be a better solution for fat removal?
According to Cosmetic Surgery Times, an ideal patient for the ATX-101 treatment is someone who only has small, localized fatty pockets. According to Dr. Patricia Walker, Kythera's Chief Medical Officer, "This product is not intended as a weight loss drug, but rather for subtle sculpting or reduction of small volumes of fat. Patients who are at or near their ideal weight, but simply cannot eliminate the fat below their chin regardless of diet or exercise would be ideal for this product". (Source: cosmeticsurgerytimes.com)
Testing is expected to end by early 2009, which means it may be ready for the FDA approval process as early as Summer 2009. If it reaches the mainstream market, most patients will need a series of treatment cycles to achieve lasting results, and the procedure can only be performed by licensed dermatologists and plastic surgeons.